Montse Brunet-Llinas
Nijmegen, GE 6534AT, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Development of Lipopeptides as Orthoflavivirin Inhibitors with Low Micromolar Broad-Spectrum Antiorthoflaviviral Activity.
Journal: Journal of medicinal chemistry
Published: October 16, 2025
Discovery of Potent, Orally Bioavailable Inhibitors of Human Cytomegalovirus.
Journal: ACS medicinal chemistry letters
Published: February 11, 2016
Hepatitis C virus serine protease: synthesis of radioactive and stable isotope-labeled potent inhibitors.
Journal: Journal of labelled compounds & radiopharmaceuticals
Published: December 10, 2013
Molecular dynamics simulations and structure-based rational design lead to allosteric HCV NS5B polymerase thumb pocket 2 inhibitor with picomolar cellular replicon potency.
Journal: Journal of medicinal chemistry
Published: June 19, 2013
Discovery of hepatitis C virus NS3-4A protease inhibitors with improved barrier to resistance and favorable liver distribution.
Journal: Journal of medicinal chemistry
Published: March 20, 2013
Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype.
Journal: Bioorganic & medicinal chemistry letters
Published: March 11, 2013
Peptide backbone replacement of hepatitis C virus NS3 serine protease C-terminal cleavage product analogs: discovery of potent succinamide inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: March 08, 2013
Synthesis and optimization of a novel series of HCV NS3 protease inhibitors: 4-arylproline analogs.
Journal: Bioorganic & medicinal chemistry letters
Published: January 25, 2013
Molecular mechanism by which a potent hepatitis C virus NS3-NS4A protease inhibitor overcomes emergence of resistance.
Journal: The Journal of biological chemistry
Published: December 29, 2012
In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335.
Journal: Antimicrobial agents and chemotherapy
Published: October 26, 2011
Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: October 13, 2011
Showing 1-11 of 11
Last Updated: 09/26/2026